Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC) Meeting Abstract

  

Authors:	Saura, C.; de Azambuja, E.; Hlauschek, D.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Nuciforo, P.; Ballestrero, A.; Fornier, M. N.; Boer, K.; Ciruelos, E.; Valero, V.; Wilson, T. R.; Stout, T. J.; Hsu, J. Y.; Shi, Y.; Piccart, M.; Gnant, M.; Baselga, J.
Abstract Title:	Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
Meeting Title:	42nd ESMO Congress (ESMO 2017)
Journal Title:	Annals of Oncology
Volume:	28
Issue:	Suppl. 5
Meeting Dates:	2017 Sep 8-12
Meeting Location:	Madrid, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2017-09-01
Start Page:	mdx440.001
Language:	English
ACCESSION:	WOS:000411324005061
DOI:	10.1093/annonc/mdx440.001
PROVIDER:	wos
Notes:	Meeting Abstract: LBA10_PR -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/117039